In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO ...

In the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion (OPDP), Sen. | In the wake of sweeping cuts ...

China's anti-graft watchdog is investigating Bi Jingquan, the former head of the China Food and Drug Administration. | ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy.

Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

Hey, AbbVie, what do you say? The Cubs are gonna strike out cancer today. | A new partnership between the Chicago-based ...

Astellas is banging the drum for patient advocacy organizations (PAOs) again. | Astellas is banging the drum for patient ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...